Ann: Breakthrough Zantrene Heart Protection Discovery, page-278

As Dr T stated, you've come into the speculative end of the investing spectrum complaining of CR's. Early mining companies, biotech or tech companies will not be producing revenue, and it will be mainly outflows. This is the nature of R&D/Exploration companies.

The important question you should be asking is how the CR's are done and when they are done, as well as how effective they are. Look at the pipeline for a biotech company, and determine how much it may cost to drive the drug to the intended target(either to FDA approval, or to a buyout pre-FDA).

Have you looked at prior announcements to determine the importance/relevance? You make reference to Bon Bons, but does that mean you also discount the other important members that have recently joined the team ie Dr David Fuller who was previously working for a CRO(working 10 years there before coming onboard here?), Professor Michael Kelso and Professor Jianjun Chen? Have you discounted that there were other drugs in the m6a space that have sold before they have even gotten to the clinic?

Warts and all? FTO is a complete unknown, there is nothing like this that has come into the clinic so it is a massive unknown.

If you'd like, banks rarely do CR's?